Survival and Glycemic Control in Patients With co-existing Squamous Cell Carcinoma and Diabetes Mellitus

Ederaine, Sophia A.; Dominguez, Johanny Lopez; Harvey, Jamison A.; Mangold, Aaron R.; Cook, Curtiss B.; Kosiorek, Heidi E.; Buras, Matthew R.; Coppola, Kyle; Karlin, Nina J.

doi:10.2144/fsoa-2020-0150

Cited by 4 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cancer patients, diabetes is associated with a poorer health-related quality of life (HRQOL) [ 20 ], higher healthcare utilization [ 21 ], and an increased risk of cancer progression and mortality [ 22 , 23 , 24 ], which highlights the clinical importance of knowing whether cancer patients are more likely to develop diabetes.…”

Section: Introductionmentioning

confidence: 99%

Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis

Yang

Liu

Thong

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Diabetes increases the risk of certain types of cancer. However, the literature regarding the incidence of diabetes after cancer diagnosis is inconsistent. We aimed to assess whether there was a higher incidence of diabetes among cancer patients by performing a systematic review and meta-analysis of results from cohort studies. Methods: A systematic electronic literature search was carried out from cohort studies regarding the incidence of diabetes in cancer patients, using the databases PubMed (MEDLINE), Embase, Web of Science, and the Cochrane Library. Random-effects meta-analyses were conducted to pool the estimates. Results: A total of 34 articles involving 360,971 cancer patients and 1,819,451 cancer-free controls were included in the meta-analysis. An increased pooled relative risk (RR) of 1.42 (95% confidence interval (CI): 1.30–1.54, I2 = 95, τ2 = 0.0551, p < 0.01) for diabetes in cancer patients was found compared with the cancer-free population. The highest relative risk was observed in the first year after cancer diagnosis (RR = 2.06; 95% CI 1.63–2.60). Conclusions: New-onset diabetes is positively associated with cancer, but this association varies according to cancer type. More prospective studies with large sample sizes and longer follow-up times are advocated to further examine the association and the underlying mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis

Yang

Liu

Thong

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Although diabetes itself is not associated with a higher incidence of skin cancer, 36 the co-occurrence of skin cancer and diabetes significantly disrupts treatment of both conditions. 37 Thus, any potential increase in skin cancer risk with commonly used diabetes treatments are a cause for concern, making the case for well conducted large observational studies. To our knowledge, this is the first such study examining the association between GLP-1 RAs and skin cancer.…”

Section: Discussionmentioning

confidence: 99%

“…However, it is difficult to assess the risk of skin cancer from these trials as they lacked generalizability to the diabetes population at large, had relatively small sample sizes and short median durations of follow‐up, 35 as well as has inconsistent reporting of skin cancer events. Although diabetes itself is not associated with a higher incidence of skin cancer, 36 the co‐occurrence of skin cancer and diabetes significantly disrupts treatment of both conditions 37 . Thus, any potential increase in skin cancer risk with commonly used diabetes treatments are a cause for concern, making the case for well conducted large observational studies.…”

Section: Discussionmentioning

confidence: 99%

Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort study

Pradhan,

Yu,

Platt

et al. 2023

Diabet Med

View full text Add to dashboard Cite

AimsThe objective of this study was to determine whether the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with an increased risk of melanoma and nonmelanoma skin cancer, separately, compared with the use of sulfonylureas among patients with type 2 diabetes.Materials and MethodsUsing the United Kingdom Clinical Practice Research Datalink (2007‐2019), we assembled two new‐user active comparator cohorts. In the first cohort assessing melanoma as the outcome, 11,786 new users of GLP‐1 RAs were compared with 208,519 new users of sulfonylureas. In the second cohort assessing nonmelanoma skin cancer as the outcome, 11,774 new users of GLP‐1 RAs were compared with 207,788 new users of sulfonylureas. Cox proportional hazards models weighted using propensity score fine stratification were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of melanoma and nonmelanoma skin cancer, respectively.ResultsCompared with sulfonylureas, GLP‐1 RAs were not associated with an increased risk of either melanoma (42.6 vs. 43.9 per 100,000 person‐years, respectively; HR 0.96, 95% CI 0.53‐1.75) or nonmelanoma skin cancer (243.9 vs. 229.9 per 100,000 person‐years, respectively; HR 1.03, 95% CI 0.80‐1.33). There was no evidence of an association between cumulative duration of use with either melanoma or nonmelanoma skin cancer. Consistent results were observed in secondary and sensitivity analyses.ConclusionsIn this population‐based cohort study, GLP‐1 RAs were not associated with an increased risk of melanoma or nonmelanoma skin cancer, compared with sulfonylureas.

show abstract

“…The results of this study confirm those of previous studies that diabetes does not affect survival in breast, colon, lung, pancreatic and prostate cancers, but similar observations have not been true in other cancer types. For instance, diabetes was associated with decreased OS in gastroesophageal and squamous cell cancers and with shorter progression-free survival in melanoma [ 11 , 12 , 16 ]. The methods of the current study; however, could be used to reexamine these relationships on a larger and broader geographic scale.…”

Section: Discussionmentioning

confidence: 99%

Cancer, Diabetes, Survival and Glycemic Control: A Large Multisite Analysis

et al. 2022

View full text Add to dashboard Cite

Aim: To determine overall survival (OS) and glycemic control in patients with cancer and diabetes. Materials & methods: Patients of our institution with breast, colon, lung, pancreas and prostate cancer were retrospectively reviewed. OS was compared between matched patients with and without diabetes, and changes in glucose value over time were assessed. Results: For 3934 patients each with and without diabetes, adjusted analysis showed no difference in OS according to diabetes status (hazard ratio: 1.07; 95% CI: 0.96–1.20). Mean glucose values decreased over time in patients with and without diabetes (p = 0.01). Conclusion: In this large study of patients with five common cancers, the co-occurrence of diabetes did not affect OS. Cancer did not adversely affect glucose levels.

show abstract

Survival and Glycemic Control in Patients With co-existing Squamous Cell Carcinoma and Diabetes Mellitus

Cited by 4 publications

References 32 publications

Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis

Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis

Glucagon like peptide‐1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population‐based cohort study

Cancer, Diabetes, Survival and Glycemic Control: A Large Multisite Analysis

Contact Info

Product

Resources

About